Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Phase 1 Unknown 30 enrolled Maxinovel Pty., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.

Timeline

Start: 2019-04-16
Primary completion: 2022-12-01
Completion: 2022-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MAX-40279-01	Unknown	—	Oral

Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Summary

Timeline

Drugs

Indications